Previous 10 | Next 10 |
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 -- -- Completed enrollment in LUMINA 1 Phase II trial of CCR2 inhibitor CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Advancing three additi...
MOUNTAIN VIEW, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 9:30 a.m. ET. ...
MOUNTAIN VIEW, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2019 financial results will be released after market close on Monday, August 5, 2019. ChemoCentryx executive management will host a conference call ...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with this Read more ...
MOUNTAIN VIEW, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Raymond James Life Sciences and MedTech Conferenc...
Editor's note: Seeking Alpha is proud to welcome Cory Jubinville as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Results for Inf...
Gainers: ReWalk Robotics (NASDAQ: RWLK ) +126% . Genocea Biosciences (NASDAQ: GNCA ) +14% . Dean Foods (NYSE: DF ) +13% . RAVE Restaurant Group (NASDAQ: RAVE ) +11% . Medley Management (NYSE: MDLY ) +10% . Neon Therapeutics (NASDAQ: NTGN ) +10% . Allena Pharmaceuticals (NASDAQ:...
InflaRx N.V. (NASDAQ: IFRX ) -87% after IFX-1 flunks mid-stage study. More news on: InflaRx N.V., GameStop Corp., ChemoCentryx, Inc., Stocks on the move, Read more ...
Market Assessment ChemoCentryx ( CCXI ) is a clinical-stage small market cap ($683M) biopharma developing innovative therapeutics predominantly for kidney diseases. Its scientific forte is chemokine biology. This is not surprising since Thomas Schall, PhD, the founder of ChemoCentryx, is a...
ChemoCentryx, Inc. (CCXI) Q1 2019 Earnings Conference Call May 06, 2019, 17:00 ET Company Participants Bill Slattery - Burns McClellan Thomas Schall - Founder, President, CEO & Chairman Susan Kanaya - EVP, Chief Financial & Administrative Officer and Secretary Conferen...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...